Characteristics | Overall (161) | ARE (51) | p value |
---|---|---|---|
Gender |  |  | p < 0.001 |
 Male (N/%) | 142/88.2% | 47/33.1% | |
 Female (N/%) | 19/11.8% | 4/21.1% | |
Age, median (range) | 62 (29–83) | – | p < 0.001 |
Pathology |  |  | p < 0.001 |
 SCC (N/%) | 104/64.6% | 37/35.6% | |
 ADC (N/%) | 51/31.7% | 13/25.5% | |
 Others (N/%) | 6/3.7% | 1/16.7% | |
RT Dose |  |  | p < 0.001 |
 Median (range) \(<\) 60 Gy | 60 (45–70) Gy |  | |
 N/% | 81/50.3% | 24/29.6% | |
Smoking |  |  | p < 0.001 |
 Activity or former (N/%) | 123/76.4% | 38/30.9% | |
 Never (N/%) | 38/23.6% | 13/34.2% | |
T Stage |  |  | p < 0.001 |
 T1 (N/%) | 10/6.2% | 1/10.0% | |
 T2 (N/%) | 70/43.5% | 24/34.3% | |
 T3 (N/%) | 35/21.7% | 11/31.4% | |
 T4 (N/%) | 46/28.6% | 16/34.8% | |
N Stage |  |  | p < 0.001 |
 N0 (N/%) | 9/5.6% | 2/22.2% | |
 N1 (N/%) | 4/2.5% | 1/25.0% | |
 N2 (N/%) | 85/52.8% | 33/38.8% | |
 N3 (N/%) | 63/39.1% | 15/23.8% | |
TNM |  |  | p < 0.001 |
 IIIA (N/%) | 54/29.2% | 20/37.0% | |
 IIIB (N/%) | 107/70.8% | 31/29.0% | |
Treatment technology |  |  | p < 0.001 |
 SCRT (N/%) | 65/40.4% | 17/26.2% | |
 CCRT (N/%) | 87/54.0% | 31/35.9% | |
 RT (N/%) | 9/5.6% | 3/33.3% | |
 ARE (N/%) | 51/31.7% | – | – |